NCT00672009View on ClinicalTrials.gov

A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

April 30, 2011

Study Completion Date

August 31, 2012

Conditions
Prostatic DiseasesGenital Neoplasms, MaleUrogenital NeoplasmsGenital Diseases, MaleAdenocarcinomaProstatic NeoplasmsNeoplasms, Glandular and EpithelialCarcinoma
Interventions
DRUG

Ixabepilone

Ixabepilone 35 mg/m\^2 intravenously over 3 hours every 21 days for 4 cycles.

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Cedars-Sinai Medical Center

OTHER